share_log

HC Wainwright & Co. Maintains Buy on Co-Diagnostics, Lowers Price Target to $6

HC Wainwright & Co. Maintains Buy on Co-Diagnostics, Lowers Price Target to $6

HC Wainwright & Co.維持Co-Diagnostics的買入,將目標價下調至6美元
Benzinga Real-time News ·  2022/11/14 06:28

HC Wainwright & Co. analyst Yi Chen maintains Co-Diagnostics (NASDAQ:CODX) with a Buy and lowers the price target from $9 to $6.

HC Wainwright & Co. 分析師陳毅維持Co-Diagnostics(納斯達克股票代碼:CODX)的買入,並將目標股價從9美元下調至6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論